Sign up
Pharma Capital

Amryt appoints new Vice President

CEO of Amryt Pharmaceutical  (LON:AMYT) Rory Nealon tells Proactive about the latest addition to the senior management team, their new Vice President, Patrick Jordan who will oversee their Lojuxta  business. Jordan is an 18-year veteran of the healthcare industry and has held senior roles at Pfizer and MSD (Merck & Co).
The company is a commercial-stage pharmaceutical company focussed on developing and producing treatments for rare and orphan diseases.
Its lead product, Lojuxta, treats a life-threatening condition called Homozygous Familial Hypercholesterolemia, which causes abnormally high levels of bad cholesterol.


View full AMYT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.